Respiratory syncytial virus (RSV) is a significant cause of bronchiolitis and pneumonia in several high health risk populations, including infants, elderly and immunocompromised individuals. Mortality in hematopoietic stem cell transplant recipients with lower respiratory tract RSV infection can exceed 80%. It has been shown that RSV replication in immunosuppressed individuals is significantly prolonged, but the contribution of pulmonary damage, if any, to the pathogenesis of RSV disease in this susceptible population is not known. In this work, we tested RI-002, a novel standardized Ig formulation containing a high level of RSV-neutralizing Ab, for its ability to control RSV infection in immunocompromised cotton rats Sigmodon hispidus. Animals immunosuppressed by repeat cyclophosphamide injections were infected with RSV and treated with RI-002. Prolonged RSV replication, characteristic of immunosuppressed cotton rats, was inhibited by RI-002 administration. Ab treatment reduced detection of systemic dissemination of viral RNA. Importantly, pulmonary interstitial inflammation and epithelial hyperplasia that were significantly elevated in immunosuppressed animals were reduced by RI-002 administration. These results indicate the potential of RI-002 to improve outcome of RSV infection in immunocompromised subjects not only by controlling viral replication, but also by reducing damage to lung parenchyma and epithelial airway lining, but further studies are needed.

Bone Marrow Transplantation (2016) 51, 119–126; doi:10.1038/bmt.2015.212; published online 14 September 2015

INTRODUCTION

Respiratory syncytial virus (RSV) is a significant cause of bronchiolitis and pneumonia in high-risk infants and children, elderly and immunocompromised individuals. Among hematopoietic stem cell transplant recipients (HSCT), RSV affects between 2 and 17% of patients, with infection progressing to lower respiratory tract infection in 17–84% of cases.1–9 The mortality rate of RSV lower respiratory tract infection in HSCT patients, if left untreated, can reach 83% or higher.10–13 Studies in patients with hematologic disorders and in recipients of HSCT show that they maintain dramatically prolonged RSV replication, with a reported median duration of 30.5 days.14

Early intervention with ribavirin (aerosolized or oral) can reduce mortality associated with RSV infection of patients with hematologic malignancies and transplant recipients, highlighting the importance of controlling viral replication in this cohort. However, a significantly higher dose of ribavirin is required to achieve the therapeutic effect.14,15 Efficacy of ribavirin therapy may be improved by combining it with the administration of intravenous immunoglobulin (IVIG) or intravenous RSV immunoglobulin (RSV-IVIG, a preparation containing 5–10 times the amount of RSV-neutralizing Ab found in standard IVIG preparations).16,17 RSV-IVIG RespiGam approved for prophylaxis of RSV infection is no longer manufactured (http://www.aetna.com/cpb/medical/data/300_399/0318.html) and the humanized monoclonal Ab palivizumab is the only currently available drug for the prevention of RSV in high-risk infants and children.18 Palivizumab use in adult patients is restricted due to cost considerations; nevertheless, it has been tested in HSCT patients as a part of the combined therapy with ribavirin. The treatment was found to be safe and well-tolerated, however, its efficacy was not conclusive.8,19

In the normal immunocompetent subject, antivirals administered after RSV infection reduce viral replication but do not ameliorate the disease.20–22 In contrast, antivirals given before infection reduce both viral replication and disease, suggesting that once triggered, the inflammatory response leads to cytokine response and subsequent pulmonary pathology that remains even after the viral load is decreased.23 As cellular infiltration of the lung is a large component of RSV-induced pulmonary damage, it has been shown using an animal model that a combination of antiviral (for example, palivizumab) and anti-inflammatory (for example, corticosteroids) treatment may represent an effective therapeutic regime.22–24 However, whether the same approach would be required for immunosuppressed individuals is not known. Pulmonary pathology in HSCT patients with RSV infection may be mediated by the lung damage caused by prolonged viral replication. In this case, treatment with a drug that has strong antiviral activity may have a higher therapeutic efficacy in immunosuppressed patients compared with immunocompetent individuals infected with RSV because of the reduction in pulmonary damage caused by excessive viral replication.

In this work, we tested a novel RSV-IVIG formulation RI-002, manufactured in compliance with the Food and Drug Administration’s standards for treating patients with immune deficiency diseases, for its ability to reduce RSV infection in normal and immunocompromised cotton rats S. hispidus. The cotton rat model
RI-002 has accurately reproduced significantly prolonged RSV replication under conditions of immunosuppression. Cotton rats were instrumental in proving efficacy of Ab immunoprophylaxis, which led to the development of both RespiGam and palivizumab. The model also confirmed that anti-RSV Ab was less effective when given after the onset of RSV infection, indicating the important contribution of host inflammatory response to infection in the pathogenesis of RSV disease. The goal of this particular work was to determine whether RI-002 can mitigate prolonged RSV replication and reduce pathology of RSV disease in immunosuppressed cotton rats.

**MATERIALS AND METHODS**

Reagents
RI-002 Intravenous Immune Globulin (Human): 10% Human IgG, prepared to contain standardized amounts of RSV-neutralizing antibodies was isolated from source plasma obtained from more than 1000 donors who were selected to have high titers of naturally occurring neutralizing Ab to RSV. Reference Ab RespiGam (Liquid SD Lot LRIVSV-02A Reference RSV-IgG, 5%) and cyclohexamide (CY) for infection (20 μg/mL USP, Baxter, Deerfield, IL, USA) were obtained from ADMA Biologics, Ramsey, NJ, USA and Blue Door Pharmco (Rockville, MD, USA), respectively.

Viruses and viral assays
The prototype A/Long strain of RSV was obtained from the American Type Culture Collection (Manassas, VA, USA). Virus was propagated in HEP-2 cells and serially plaque-purified to reduce defective-interfering particles. A single pool of RSV A/Long (3 x 10⁴ plaque-forming unit (PFU)/mL) was used for the studies described herein. RSV viral titers in the lungs of infected animals were determined by plaque assay.

Animals and animal studies
Inbred S. hispidus cotton rats were obtained from a colony maintained at the Sigmodir Biosystems, Inc. Six- to eight-week-old inbred female cotton rats were used for the studies without the need for additional randomization. Animals were housed in large polycarbonate cages and were fed a standard diet of rodent chow and water. The colony was monitored for Ab to adventitious respiratory viruses and other common rodent pathogens and no such Ab were found. All studies were conducted under applicable laws and guidelines and after approval from the Institutional Animal Care and Use Committee of the Sigmovir Biosystems, Inc.

**RESULTS**

Efficacy of RI-002 against RSV infection in normal cotton rats
To verify the antiviral potency of RI-002 prophylaxis, normal cotton rats were inoculated i.p. with 500, 750 or 1000 mg/kg of RI-002 and infected with 10⁵ PFU of RSV A/Long per animal 24 h later. Lungs and noses were harvested for viral titration 4 days after infection. Viral load in RSV-infected, RI-002-treated animals was compared with that in RSV-infected animals treated with saline or inoculated with positive control reference RSV-IgG formulation RespiGam (750 mg/kg). Saline-treated, RSV-infected animals had 4.7 and 5 Log₁₀ PFU/g of RSV in the lung and nose tissue, respectively (Figure 1a). RI-002 completely protected the lung against RSV replication at all doses tested. Significant reduction of viral replication in the nose was also achieved. In the lungs, protection afforded by RI-002 was improved as compared with that induced by the reference RespiGam formulation. Levels of RSV-neutralizing Ab were quantified by a microneutralization assay of serum collected immediately before infection and again at the time the animal was killed (Table 1). The data show dose-response serum RSV-neutralizing titers, which correlated with the protection evidenced by the lung and nose RSV viral titers in the cotton rat tissues.

To determine the ability of RI-002 to reduce RSV load when administered after infection (RI-002 therapy), animals were infected with RSV and treated one day later with RI-002. Treatment with 1500 mg/kg RI-002 completely suppressed viral load in the lungs of infected animals on day 4 post infection (Figure 1b). Treatment with 750 mg/kg RI-002 abolished replication of RSV in the lungs of infected animals.

Histopathology analysis
Lungs were prepared for histopathology analysis as previously described and scored blindly for peribronchiolitis (inflammatory cells around small airways), perivascularitis (inflammatory cells around small blood vessels), alveolitis (inflammatory cells within alveolar spaces) and interstitial pneumonitis (inflammatory cell infiltration and thickening of alveolar walls). Each parameter was scored on a 0–4 scale. Epithelial damage was evaluated as a hyperplasia of airway epithelial cell lining, multilayered cell arrangement and small, papillae-like structures projecting into the airway lumens and was scored on a 0–3 scale (0 = absent, 1 = minimal, 2 = mild, 3 = moderate).

Quantitative reverse-transcription PCR analysis of RSV gene expression
Expression of RSV NS1 mRNA was analyzed in RNA extracted from different organs by real-time quantitative SYBR Green PCR as previously described.

Neutralizing Ab assay
Anti-RSV-neutralizing titers in the cotton rat serum samples were determined by microneutralization assay as previously described. In brief, serum dilutions were incubated with ~ 50 PFU of RSV A2 strain for 30 min at room temperature, followed by the addition of 1.5 x 10⁴ HEP-2 cells in 96-well culture plates. After 3 days, the quantity of RSV Ag was determined by RSV Enzyme Immunoassay using a monoclonal Ab to the RSV F protein. The neutralizing titer was defined as the serum dilution that results in a 50% reduction in color development.
Figure 1. RI-002 prophylaxis and therapy of RSV infection in normal cotton rats. (a) RI-002 prophylaxis in normal cotton rats. Animals were inoculated with the indicated amount of RI-002 i.p. and 24 h later challenged with $10^5$ PFU of RSV A/Long per animal. Four days after infection, animals were killed and lung and nose samples were collected for viral titration by plaque assay. Control animals were infected with RSV 24 h after i.p. administration of reference Ab RespiGam, 750 mg/kg or saline. (b) RI-002 therapy in normal cotton rats. Animals were infected with $10^5$ PFU of RSV A/Long per animal and 24 h later inoculated with the indicated amount of RI-002 i.p. Three days later, animals were killed and lung and nose samples were collected for viral titration by plaque assay. Control animals were infected with RSV, inoculated with saline 24 h later and also killed on day 4 post infection. Results represent the geomean ± s.e. for 5–10 animals per group. *P < 0.05 when compared with RSV-infected animals treated with saline.

Table 1. RSV-neutralizing Ab titer in serum of cotton rats inoculated with RI-002 or reference RSV-IVIG RespiGam

| Group               | Animal number | Predose (d-1) | Day 0 | Day 4 | Day 0 GeoMean | Day 0, s.d. | Day 4 GeoMean | Day 4, s.d. |
|---------------------|---------------|---------------|-------|-------|--------------|-------------|--------------|-------------|
| (A) Saline          | 89332         | <7.73         | <7.73 | <7.73 | NA           |
| (B) RI-002, 500 mg/kg | 89333         | <7.73         | <7.73 | <7.73 | 11.43        | 0.27        | 11.03        | 0.27        |
| (C) RI-002, 750 mg/kg | 89334         | <7.73         | 11.23 | 11.23 | <7.73        | 11.73       | <7.73        | 10.73       |
| (D) RI-002, 1000 mg/kg | 89335        | <7.73         | 13.23 | 11.73 | <7.73        | 12.62       | 0.42         | 11.32       | 0.42        |
| (E) Ref RSV-IVIG, 750 mg/kg | 89336       | <7.73         | 12.23 | 10.73 | <7.73        | 12.82       | 0.65         | 11.1        | 0.96        |

Abbreviations: IVIG = intravenous immunoglobulin; RSV = respiratory syncytial virus. Animals were inoculated i.p. with the indicated amount of RI-002, reference RSV-IVIG RespiGam or saline. Twenty-four hours later, blood was collected for serum-neutralizing Ab measurement and animals were challenged with $10^5$ PFU of RSV A/Long per animal. Four days after infection, the second blood sample was collected for microneutralizing Ab assay. Log2 neutralizing titer for individual samples and group geomean and s.d. are shown.
the lungs of two out of five animals, with barely detectable virus isolated from the remaining three animals in the group. RSV replication in the nose was also reduced in RI-002-treated animals in a dose-dependent manner.

Efficacy of RI-002 against RSV infection in immunosuppressed cotton rats
Cotton rats were immunosuppressed via repeat cyclophosphamide treatment administered over a 3-week period (Figure 2a).
Immunosuppressed animals were infected with RSV A/Long (10^5 PFU per animal) and treated with RI-002 or saline on days 1, 4 and 7 post infection. Two different treatment regimes were used: the high/low/low (H/L/L) regime of 1500 mg/kg RI-002 given on day 1 post infection, followed by two doses of 750 mg/kg given on days 4 and 7 post infection; and the high/high/high (H/H/H) regime of 1500 mg/kg RI-002 given on all three days of treatment. Animals were killed for analysis on days 4 and 10 post infection. Blood samples collected before each animal was killed were used to verify the drop in white blood cell (WBC) and lymphocyte counts in all immunosuppressed cotton rats, and a rise in serum RSV-neutralizing Ab titer in RI-002-treated animals (Figure 2b).

Significantly delayed viral clearance was seen in immunosuppressed cotton rats infected with RSV (Figure 3). Although normal cotton rats treated with saline cleared RSV by day 10 post infection, immunosuppressed saline-treated animals had ~6 log10 PFU of virus in their lungs and noses at that time. Immunosuppressed cotton rats inoculated with RI-002 after RSV challenge showed ~99.9% reduction in viral load in the lung and nose at days 4 and 10 post infection when compared with saline-treated, immunosuppressed cotton rats. Both H/L/L and H/H/H regimes of treatment were effective in suppressing viral replication.

Results represent the mean ± s.e. for 5 animals per group. *P < 0.05 when compared to RSV-infected immunosuppressed animals treated with saline and killed on the same day.

To determine whether RI-002 has an effect on pulmonary pathology associated with prolonged RSV replication in immunosuppressed animals, lung tissue was collected on day 10 post infection. Immunosuppressed animals had more severe inflammation in the lung parenchyma (interstitial pneumonia) than non-immunosuppressed animals (Figures 4a and b). Immunosuppression and RSV infection were also associated with significant hyperplasia of the mucosal epithelium of the conducting airways, which was absent in non-immunosuppressed, RSV-infected animals (Figures 4a and b, compare top and bottom panels). Immunosuppressed, RSV-infected animals treated with a high-dose antiviral regime had little to no inflammation in the parenchyma and a significantly reduced epithelial hyperplasia (Figure 4b, compare top and middle panels), whereas intermediate-dose treatment was slightly less effective at reducing epithelial damage. These results suggest that the high-dose antiviral regimen reduces both pneumonia and airway epithelial hyperplasia in immunosuppressed animals infected with RSV. As the hyperplasia is a likely response to airway epithelial injury, these findings suggest that the high-dose antiviral regime may have either protected the animals from past or ongoing bronchioal injury or may have enhanced recovery of the airway epithelium of immunosuppressed animals after the viral infection. RSV gene expression in organs outside of the respiratory tract was evaluated in immunosuppressed cotton rats infected with RSV. Samples of the liver and kidney were collected on day 10 post infection and analyzed by real-time PCR. Liver and kidney of immunosuppressed RSV-infected animals treated with saline had elevated expression of the RSV N51 gene compared with the liver and kidney samples from normal animals infected with RSV and treated with saline (Figure 5). Although the differences failed to reach statistical significance, RI-002 treatment of immunosuppressed, RSV-infected animals appeared to reduce RSV N51 expression in the liver and kidney to the basal level detected in normal cotton rats infected with RSV.

RI-002 IVIG was also used to evaluate prophylactic efficacy of RSV-IVIG against RSV disease in immunosuppressed animals. Cotton rats were immunosuppressed with CY and treated with RI-002 one day before RSV infection, and on days 4 and 8 post RSV infection in a total of three repeated doses of 1500 mg/kg or 750 mg/kg. Lungs of immunosuppressed animals treated with 1500 mg/kg were completely protected against RSV replication on both days 4 and 10 post infection (Figure 6). Animals treated with 750 mg/kg RSVIG had no detectable viral replication in the lungs on day 4 post infection, and minimal detectable replication (only two out of five animals in a group had a few plaques) recorded for day 10 samples.

DISCUSSION

The studies described here demonstrate that RI-002 treatment can significantly improve outcome of RSV disease in immunocompromised cotton rats. The treatment was found to accelerate viral clearance and to reduce damage to pulmonary tissue and airway

Figure 2. The model of RI-002 therapy of RSV infection in immunosuppressed cotton rats. (a) Immunosuppression was induced by treating animals with 50 mg/kg of cyclophosphamide (CY) three times a week over the course of 18 days before RSV infection. On day 21, animals were infected with 10^5 PFU of RSV A/Long per animal. On days 1, 4 and 7 post infection, RI-002 treatment (Ab) was administered. Groups of animals were killed on days 4 and 10 post infection for sample collection. CY treatment was continued until the end of the study. As an internal control for RSV infection without immunosuppression, age-matched normal animals were infected with RSV, treated with saline and killed on days 4 and 10 post infection. (b) White blood cell (WBC) count, lymphocyte count and serum RSV-neutralizing Ab were quantified in blood samples collected from all animals immediately before killing the animal on days 4 and 10 post infection. RI-002 treatment was given as a high/low/low (H/L/L) regime of 1500 mg/kg followed by two doses of 750 mg/kg, or as high/high/high (H/H/H) regime of 1500 mg/kg given three times. Control immunosuppressed RSV-infected animals were inoculated i.p. with saline. Experiments included five animals per group; results represent the geomean ± s.e.

Figure 3. Effect of RI-002 therapy on RSV replication in immunosuppressed cotton rats. Pulmonary and nasal viral titers (VT) were quantified by plaque assay in samples collected from normal and immunosuppressed cotton rats on days 4 and 10 post infection. Results represent the mean ± s.e. for 5 animals per group. *P < 0.05 when compared to RSV-infected immunosuppressed animals treated with saline and killed on the same day.

© 2016 Macmillan Publishers Limited Bone Marrow Transplantation (2016) 119 – 126
lining. Repeat administration of RI-002 was used to achieve the desired effect, based on the earlier observation that an insufficient number of treatments can lead to rebound RSV replication in immunosuppressed animals undergoing Ab therapy. A regime consisting of three administrations of 1500 mg/kg RI-002 was largely comparable in antiviral efficacy to a combination treatment that included one dose of 1500 mg/kg followed by two doses of 750 mg/kg. However, the high-dose treatment of repeat 1500 mg/kg RI-002 doses appeared to be more effective in restoring the pulmonary histology to the level similar to that seen in normal cotton rats infected with RSV.

In normal cotton rats, a single administration of 750 or 1000 mg/kg RI-002 given prophylactically inhibited RSV replication in the lower respiratory tract, reducing viral titers to undetectable level. Stronger antiviral effects of RI-002 correlated with higher serum RSV-neutralizing Ab titers achieved one day after Ab inoculation, consistent with the previously established correlation between serum RSV-neutralizing Ab titers and RSV load. RI-002 had a strong antiviral effect whether given prophylactically or therapeutically. Successful prophylaxis of immunosuppressed subjects with RI-002 would be important in the event of RSV outbreak in HSCT units.

**Figure 4.** Effect of RI-002 therapy on pulmonary histopathology in RSV-infected immunosuppressed cotton rats. Lung samples were collected from RSV-infected animals on day 10 post infection (details are described in Figure 3 legend). (a) Pulmonary histopathology was evaluated in hematoxylin and eosin (H&E) slides in each of the following categories: peribronchiolitis (Peribr), perivasculitis (Perivasc), interstitial inflammation (Interst), alveolitis (Alveol) and epithelial hyperplasia (Epith.hyp.). Results represent the mean ± s.e. for five animals per group. *P < 0.05 when compared with RSV-infected immunosuppressed animals treated with saline. (b) Photomicrographs of lung sections with focus on terminal bronchioles and surrounding parenchyma. The top panel shows the lung of immunosuppressed, RSV-infected animal treated with saline. Alveolar septa is thickened by infiltrates of inflammatory cells (interstitial pneumonia). Exudates into the alveolar air spaces (alveolitis) are visible. Note the hyperplasia of the bronchiolar mucosal epithelium. The inset is a ×400 snapshot of a terminal bronchiole that shows that epithelial cells are haphazardly piled into multiple layers. The middle panel shows the lung of an immunosuppressed, RSV-infected animal treated with high-dose regime of antivirals (H/H/H RI-002). Lung damage is significantly reduced. Alveolitis, interstitial pneumonia and epithelial hyperplasia are minimal to absent. The bottom panel corresponds to a normal, RSV-infected animal treated with saline. Bronchiolar epithelial hyperplasia is not apparent. Alveolitis and interstitial pneumonia are minimal in this focus. H&E stain, ×200.

**Figure 5.** Effect of RI-002 therapy on RSV detection outside of respiratory tract. Liver and kidney samples were collected from RSV-infected animals on day 10 post infection (details are described in Figure 3 legend). Expression of RSV NS1 mRNA was quantified by real-time PCR and normalized by β-actin mRNA in the corresponding organ. Results represent the mean ± s.e. for five animals per group.

Bone Marrow Transplantation (2016) 119–126 © 2016 Macmillan Publishers Limited
Figure 6. Effect of RI-002 prophylaxis on RSV replication in immunosuppressed cotton rats. Cotton rats were immunosuppressed with cyclophosphamide and inoculated with RI-002 at 750 (low dose) or 1500 mg/kg (high dose). Twenty-four hours later, animals were infected with 10^6 PFU of RSV A/Long per animal. On days 4 and 8 post infection, RI-002 treatment was repeated in the same dose as the original one. Groups of animals were killed on days 4 and 10 post infection and lungs were collected for viral titration (VT). Control animals were immunosuppressed, infected with RSV and inoculated with saline one day before and on days 4 and 8 post infection. Results represent the mean ± s.e. for 4–5 animals per group. *P < 0.05 when compared with RSV-infected animals treated with saline killed on the same day.

RI-002 infusion ameliorated pulmonary pathology associated with prolonged RSV replication in immunosuppressed cotton rats. Both elevated interstitial pneumonia and epithelial hyperplasia, features characteristic of immunosuppressed RSV-infected animals, were strongly reduced by RI-002. Antiviral therapy, therefore, appears more effective as a stand-alone treatment against pulmonary disease in immunosuppressed compared with normal cotton rats infected with RSV.22,23 This suggests that excessive viral replication may indeed be a driving factor of RSV pathogenesis in immunosuppressed subjects and that RSV antivirals may have a higher therapeutic potential as a stand-alone treatment in immunosuppressed patients, but future studies in the human patient population are needed to confirm this hypothesis. In addition to antiviral activity, an anti-inflammatory activity, which is present in IVIG27-39 could be beneficial and could have contributed to the disease-ameliorating effect seen in this work. Dissemination of microbial pathogens outside of primary target organs is also a significant problem for bone marrow transplant recipients.40 Dissemination of RSV in immunocompromised patients is not well documented, but RSV RNA has been detected in the blood and found to correlate with poor outcome of RSV lower respiratory tract disease in HSCT recipients.41,42 Our results show that detection of RSV RNA outside of respiratory tract of immunosuppressed cotton rats was reduced by RI-002 treatment.

There is a well-defined segment of patients with immune deficiency diseases that require regular infusions of Ig to reconstitute their deficient humoral Ab compartment and who are also extremely susceptible to RSV disease.43-45 With the withdrawal of RespiGam from the market, an important IVIG product in the arsenal for controlling RSV disease in vulnerable populations is no longer available. The improved efficacy of IVIG vs palivizumab against RSV in HSCT patients17,19 suggested that broader spectrum Ab may be required. A pivotal phase III RI-002 clinical trial in patients with immune deficiency disease has recently been completed.46 The favorable secondary outcomes that were achieved suggest that the unique Ab profile of RI-002 may have contributed to the positive results. RI-002 not only has higher titer Ab to RSV, but also contains significantly higher titers of Ab to other respiratory viruses including coronavirus, parainfluenza virus, metapneumovirus and influenza virus (manuscript submitted for publication). Multiple respiratory viruses, including adenoviruses, rhinoviruses and coronaviruses have higher infection rates in HSCT recipients and may have prolonged viral replication in these subjects. Lower respiratory tract infection complication rates are high for RSV, influenza, parainfluenza, adenoviruses and human metapneumovirus (reviewed in Shah et al.47), suggesting that the polyvalent and broad antiviral characteristics of RIIG may be important in this patient population.

CONFLICT OF INTEREST

Sigmovir Biosystems was funded by ADMA to test RI-002 in the cotton rat model.

ACKNOWLEDGEMENTS

We thank Hannah Sanford-Crane, Lauren Hippler, Julio Canas, Charles Smith and Martha Malache for help with the animal studies. We also thank Tom March for help with evaluating pulmonary histopathology and Maryanne Formica for technical assistance with the neutralizing assays.

REFERENCES

1 Whimbey E, Champlin RE, Couch RB, Englund JA, Goodrich JM, Raad I et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996; 22: 778–782.
2 Khanna N, Widmer AF, Decker M, Steffen I, Halter J, Heim D et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008; 46: 402–412.
3 Raboni SM, Nogueira MB, Tsujiya LR, Takahashi GA, Pereira LA, Pasquiun R et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 2003; 76: 142–146.
4 Martino R, Porras RP, Rabellia N, Williams JV, Ramaia E, Margall N et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 2005; 11: 781–796.
5 Schiffier JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica 2009; 94: 1101–1108.
6 Peck AJ, Englund JA, Kyppers J, Guthrie KA, Corey L, Morrow R et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007; 110: 1681–1688.
7 Ljungman P, Ward KN, Crooms BN, Parker A, Martino R, Shaw PJ et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001; 28: 479–484.
8 Boeckh M, Berrey MM, Boweren RA, Crawford SW, Balske J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001; 184: 350–354.
9 Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H et al. NIAID Collaborative Antiviral Study Group. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 44: 245–249.
10 Champlin RE, Whimbey E. Community respiratory virus infections in bone marrow transplant recipients: the M.D. Anderson Cancer Center experience. Biol Blood Marrow Transplant 2001; 7 Suppl: 85–105.
11 Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001; 7 Suppl: 115–115.
12 Wingard JR, Nichols WG, McDonald GB. Supportive care. Hematology Am Soc Hematol Educat Program 2004; 1: 372–389.
13 Shah DP, Ghantoji SS, Ariza-Heredia EJ, Shah JN, El Taoum KF, Shah PK et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood 2014; 123: 3263–3268.
14 Lehnert N, Schnitzler P, Gesi S, Puthenparambil J, Benz MA, Alber B et al. Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant 2013; 48: 1548–1553.
15 Casey J, Morris K, Narayana M, Nakagaki M, Kennedy GA. Oral ribavirin for treatment of respiratory syncytial virus and parainfluenza 3 virus infections post
allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2013; 48: 1558–1561.

16 Whimbey E, Champlin RE, Englund JA, Mirza NQ, Piedra PA, Goodrich JM et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 393–399.

17 Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117: 2755–2763.

18 The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531–537.

19 DeFoortbrune FS, Robin M, Porcher R, Scieux C, de Latour RP, Ferry C et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007; 45: 1029–1024.

20 Rodriguez WJ, Gruber WC, Welliver RC, Simoes EA, Meissner HC et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics 1997; 99: 454–461.

21 Rodriguez WJ, Gruber WC, Groothuis JR, Simoes EA, Rosas AJ, Lepow M et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 1997; 100: 937–942.

22 Prince GA, Mathews A, Curtis SJ, Porter DD. Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model with systemically administered monoclonal antibody (palivizumab) and glucocorticosteroid. J Infect Dis 2000; 182: 1326–1330.

23 Boukhvalova MS, Yim KC, Kuhn KH, Hemming JP, Prince GA, Porter DD et al. Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment. J Infect Dis 2007; 195: S11–S18.

24 Ottolini MG, Curtis SJ, Porter DD, Mathews A, Richardson JY, Hemming VG et al. Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob Agents Chemother 2002; 46: 2299–2302.

25 Johnson RA, Prince GA, Suffin SC, Horswood RL, Chanock RM. Respiratory syncytial virus infection in cyclophosphamide-treated cotton rats. Infect Immun 1982; 37: 369–373.

26 Prince GA, Hemming VG, Horswood RL, Chanock RM. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res 1985; 3: 193–206.

27 Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993; 329: 1524–1530.

28 The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99: 93–99.

29 Gupta CK, Leszczynski J, Gupta RK, Silber GR. Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine 1996; 14: 1417–1420.

30 Prince GA, Jenson AB, Horswood RL, Camacho E, Chanock RM. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 1978; 93: 771–791.

31 Prince GA, Curtis SJ, Yim KC, Porter DD. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 2001; 82: 2881–2888.

32 Boukhvalova MS, Prince GA, Blanco JC. Respiratory syncytial virus infects and abortively replicates in the lungs in spite of preexisting immunity. J Virol 2007; 81: 9434–9450.

33 Boukhvalova MS, Yim KC, Prince GA, Blanco JC. Methods for monitoring dynamics of pulmonary RSV replication by viral culture and by real-time reverse transcription-PCR in vivo: Detection of abortive viral replication. Curr Protoc Cell Biol 2010; Chapter 26: Unit266.

34 Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 1998; 177: 463–466.

35 Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 2004; 189: 233–238.

36 Ottolini MG, Porter DD, Hemming VG, Zimmerman MN, Schwab NM, Prince GA. Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant 1999; 24: 41–45.

37 Nimmejahn F, Ravetch JV. The antiflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007; 204: 11–15.

38 Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008; 105: 19571–19578.

39 Kaveri SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 2012; 11: 792–794.

40 LaRocca MT, Burgert SJ. Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation. Clin Microbiol Rev 1997; 10: 277–297.

41 Campbell AP, Chien JW, Kyuppers J, Englund JA, Wald A, Guthrie KA et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. J Infect Dis 2010; 201: 1404–1413.

42 Waghmare A, Campbell AP, Xie H, Seo S, Kyuppers J, Leisening W et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis 2013; 57: 1731–1741.

43 Asner S, Stephens D, Pedulla P, Richardson SE, Robinson J, Allen U. Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children. Pediatr Infect Dis J 2013; 32: 1073–1076.

44 Hong J, Knutten AP. Pulmonary disease in primary immunodeficiency disorders. Ped Allergy Immunol Pulmonol 2013; 86: 67–68.

45 Lanari M, Vandini S, Capretti MG, Lazzarotto T, Faldella G. Respiratory syncytial virus infections in infants affected by primary immunodeficiency. J Immunol Res 2014; 2014: 850831.

46 Mond J, Cunningham-Rundles C, Falsey A, Forbes L, Grossman A, Harris J et al. Pharmacokinetics of RI-002, an investigational IVIG preparation. J Allergy Clin Immunol 2015; 135: 286.